AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Vildako M 50mg/500mg Tablet

Prescription Icon
Prescription Required

Marketer

Athiko Life Sciences

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Vildako M 50mg/500mg Tablet

Combiflex DM 50mg/500mg tablets combine two medications to manage elevated blood glucose in patients with type 2 diabetes. This dual action helps prevent severe diabetic complications like renal impairment and vision loss, potentially lowering the risk of cardiovascular events. Combiflex DM 50mg/500mg may be used independently or in conjunction with other anti-diabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is individualized based on your health status, glucose levels, and existing medications. Taking it with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes effectiveness; discontinuation should only occur under medical supervision. Adherence to your physician's dietary and exercise plan is crucial for effective diabetes management; lifestyle significantly impacts blood sugar control. Commonly reported side effects include nausea, vomiting, diarrhea, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, especially when combined with insulin or sulfonylureas; learn to recognize and treat this condition. This medication is not universally suitable. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Interactions with other drugs are possible; disclose all medications to ensure safety. Alcohol should be minimized due to its hypoglycemic effect. Your physician will monitor kidney function and blood glucose levels throughout therapy.

Uses of Vildako M 50mg/500mg Tablet

Managing Type 2 Diabetes

Major Benefits of Vildako M 50mg/500mg Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the Vildako M 50mg/500mg Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

Common Side effects of Vildako M 50mg/500mg Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Vildako M 50mg/500mg Tablet:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the Vildako M 50mg/500mg Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

How Vildako M 50mg/500mg Tablet works:

Vildako M 50mg/500mg tablets contain sitagliptin and metformin, working synergistically to manage blood glucose levels. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This dual action results in improved glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Vildako M 50mg/500mg tablets with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Vildako M 50mg/500mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Using Vildako M 50mg/500mg tablets while breastfeeding is likely inadvisable. Available data from humans indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Vildako M 50mg/500mg tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates use of Vildako M 50mg/500mg tablets. Physician consultation is necessary. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

Patients with liver impairment should likely avoid Vildako M 50mg/500mg tablets due to potential safety concerns. Medical advice is recommended.

What if you forget to take Vildako M 50mg/500mg Tablet :

Should you forget to take your Vildako M 50mg/500mg Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosage regimen. Avoid taking a double dose.

Facts to Know About Vildako M 50mg/500mg Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Vildako M 50mg/500mg Tablet

Vildako M 50mg/500mg tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Vildako M 50mg/500mg tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and balance problems), if left untreated. Preventive annual vitamin B12 supplementation is recommended by some researchers.
Vildako M 50mg/500mg Tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Vildako M 50mg/500mg Tablets are contraindicated in patients with known allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Vildako 50mg/500mg tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Vildako M 50mg/500mg Tablets can cause lactic acidosis (MALA, or Metformin-associated lactic acidosis), a serious medical emergency involving high blood lactic acid levels. This rare side effect is why the medication is avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Vildako M 50mg/500mg tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Vildako M 50mg/500mg Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Vildako M 50mg/500mg Tablets are contraindicated in patients with known allergies to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Vildako M 50mg/500mg tablets with alcohol is unsafe and may raise the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a potential side effect of Vildako M 50mg/500mg Tablets. This occurs due to elevated blood lactic acid levels. Because it's rare, metformin is avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Vildako M 50mg/500mg Tablets can lead to vitamin B12 deficiency by impairing its absorption. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Dispose of any unused medication properly and keep it out of reach of children, pets, and others.
Vildako M 50mg/500mg tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Vildako M 50mg/500mg Tablet may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Vildako M 50mg/500mg Tablets are contraindicated in patients with allergies to any ingredient or excipient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Vildako 50mg/500mg tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid, is a potential side effect of Vildako M 50mg/500mg Tablet (containing metformin). Also known as metformin-associated lactic acidosis (MALA), it's rare but more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Vildako M 50mg/500mg Tablet can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes (including balance problems). To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Vildako M 50mg/500mg Tabl...
183